Patients with severe eosinophilic asthma, who participated in three different Phase 3 trials of benralizumab (brand name Fasenra) and then enrolled in a long-term trial of the drug’s efficacy and safety, continued to experience fewer exacerbations and improved pulmonary function and quality of life.
Source: EurekaAlert, https://www.eurekalert.org